pertuzumab

The drug is intended for the treatment of adult patients with HER2-positive breast cancer. It is used in early-stage cancer (neoadjuvant therapy before treatment or adjuvant therapy after it), as well as in metastatic or locally recurrent breast cancer in combination with docetaxel.

Form: solution for injection

ATC: L01FY01

Manufacturer: F. Hoffmann-La Roche Ltd

The drug is used for the treatment of adult patients with HER2-positive early breast cancer (both pre- and post-surgery), as well as for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with chemotherapy.

Form: solution for injection

ATC: L01FY01

Manufacturer: F. Hoffmann-La Roche Ltd

The drug is used to treat various forms of breast cancer, specifically early-stage cancer (both pre- and post-surgery) and metastatic or locally recurrent cancer that is HER2-positive.

Form: concentrate for infusion solution

ATC: L01FD02

Manufacturer: Roche Diagnostics GmbH (manufacturing of unpackaged products, primary packaging, quality control testing)